We help our customers conduct cost-efficient observational studies worldwide
Along with clinical specialists, our team of epidemiologists, statisticians, clinicians, health economists and qualitative researchers conduct effective field, secondary data and hybrid observational studies to achieve our client’s goals.
OXON offers proven experience and a large portfolio of studies in all major therapy areas, orphan conditions, pregnancy and risk minimization, combining clinical, epidemiological and statistical expertise particularly in the areas of oncology, neuroscience, cardio metabolic and COVID-19.
Our Core Therapeutic Areas expertise
OXON has working experience on:
We have worked on a pragmatic trial of a Gliflozin (SGLT2i).
We receive scientific consultation from Stuart Pocock, Professor of Medical Statistics, London School of Hygiene & Tropical Medicine, who is an international leader in diabetes trials and registries.
Our staff have worked on studies in Obesity, High blood pressure, Lipids, Anti-coagulants, Anti-thrombotic and Heart failure, having completed studies with cardiovascular and Stroke safety endpoints. Several of these projects have led to full publications in The Lancet, with OXON authors.
Stuart Pocock, Professor of Medical Statistics, London School of Hygiene & Tropical Medicine, who is an international leader in cardiovascular trials and registries and evaluation of Cardiovascular safety issues, consults us in this field.
OXON has worked on studies in:
– Solid cancers: Lung, Breast, Colorectal, Urothelial, Melanoma.
– Haematologic cancers: Multiple myeloma and Leukaemia, Oncologic pain.
We have experience of multi-country data collection and secondary data PASS studies in Europe in acute lymphoblastic leukaemia, gastrointestinal cancer, and lung and urothelial cancers, and a track record of approval of PASS protocols and study reports, with almost no changes required.
Furthermore, we work together with Clinical oncologists and Haematologists with whom we consult closely and can analyse the Systemic Anti-Cancer Therapy (SACT) database in the UK.
OXON has worked on studies in Alzheimer’s disease and other dementias, Parkinson’s disease, Multiple sclerosis, Epilepsy, Schizophrenia, Anti-Psychotics, Anti-depressants, with publications in The Lancet, among others.
One of our senior clinical epidemiologists is chief author of the international textbook: ´Evidence-based Dementia Practice´, published by Wiley-Blackwells, Oxford and was Founding Editor of the Cochrane Dementia Group.
OXON is proud to have led the retrospective cohort study: ‘Blood cholesterol and risk of dementia in a retrospective cohort of over 1.8 million people over two decades’, recently published in Lancet Healthy Longevity, which provides the strongest evidence so far on the relationship between blood cholesterol and dementia and Alzheimer’s disease.
Observational studies are an important approach for studying health outcomes in Orphan Diseases. Several advanced observational methods that are used to study outcomes in common conditions are also used for studying rare diseases (for example, crossover designs and propensity scores).
OXON has worked on a wide range of rare diseases such as studies in Fabry, Gaucher, Pompe, and Spinal Muscular Atrophy. These studies include different approaches, with emphasis on the use of ultra-rare orphan disease registries.
We have worked on studies in Rheumatoid Arthritis, Atopic Dermatitis, Psoriasis, Organ Transplant Rejection, and other medical conditions from an immunologic point of view. We have recently successfully finalised a PAS Evaluation study in Transplant Rejection.
OXON has worked on studies in Influenza, Pneumococcal Disease, Diphtheria-Tetanus-Pertussis, Rotavirus, and Herpes Zoster. Our experience in this field does not only cover PASS studies, but also feasibility assessments and the use of databases in several European countries.
Our motivation in the clinical respiratory field has promoted innovative approaches in feasibility studies, as well as other types of studies related to COPD, Asthma and Allergic Bronchopulmonary Aspergillosis.
We have experience in studies in Keratoconjunctivitis.
We have worked on several studies involving children: Vaccines, Leukaemia, Rotavirus, and others. We have experience in adapting the study and study documentation such as parental consent and children’s assent forms to the appropriate age group and ensure achievement of the objectives.
OXON has developed a novel approach to studying drug exposure during pregnancy, with a follow-up on pregnancy, birth, infant and childhood outcomes with the use of prospective pregnancy registries and hybrid database approaches. This method provides many advantages compared to traditional pregnancy registries.